Literature DB >> 16134728

Prevalence of Fc-gammaR chain expression in CD4+ T cells of patients with systemic lupus erythematosus.

L Butkiewicz1, S Duriagin, R Laddach, H Chwalinska-Sadowska, P P Jagodzinski.   

Abstract

OBJECTIVE: To determine the upregulation of transcript and protein levels of the T cell receptor (TCR)/CD3-Fc-gammaR chain in CD4+ T cells of systemic lupus erythematosus (SLE) patients with different clinical disease activity scored on the SLE Disease Activity Index (SLEDAI) scale.
METHODS: CD4+ cells were isolated by the positive biomagnetic separation technique. Quantitative analysis of Fc-gammaR cDNA was carried out by using the real-time quantitative polymerase chain reaction (RQ-PCR) SYBR Green I system. Protein levels of Fc-gammaR in CD4+ T cells were determined by Western blotting analysis.
RESULTS: We observed significantly higher transcript and protein levels of the Fc-gammaR chain in CD4+ T cells of SLE patients (n = 45) than in healthy individuals (n = 26). The increase in Fc-gammaR expression was observed in 97.8% of SLE patients. Spearman statistical analysis suggests that the protein level of Fc-gammaR in CD4+ T cells may correlate with SLE activity scored by the SLEDAI scale (R = 0.556, p < 0.00006, respectively).
CONCLUSION: The high prevalence of the Fc-gammaR chain in CD4+ T cells of SLE patients may indicate an important role for this molecule in the pathogenesis of SLE.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16134728     DOI: 10.1080/03009740510018688

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  2 in total

1.  FcgammaRIII engagement provides activating signals to NKT cells in antibody-induced joint inflammation.

Authors:  Hye Young Kim; Sanghee Kim; Doo Hyun Chung
Journal:  J Clin Invest       Date:  2006-08-17       Impact factor: 14.808

2.  Prevalence of ZAP-70, LAT, SLP-76, and DNA methyltransferase 1 expression in CD4+ T cells of patients with systemic lupus erythematosus.

Authors:  Radosław Januchowski; Mariusz Wudarski; Hanna Chwalińska-Sadowska; Paweł P Jagodzinski
Journal:  Clin Rheumatol       Date:  2007-05-11       Impact factor: 3.650

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.